Where Pharming Stands With Analysts
Portfolio Pulse from Benzinga Insights
Pharming (NASDAQ:PHAR) has received consistent 'Buy' ratings from analysts, with a stable 12-month price target of $37.00. The company has shown a 34.97% revenue growth over the past three months, though its growth rate is below the healthcare sector average. Pharming's financial health is strong, with efficient cost management and a prudent debt strategy.
October 15, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pharming has received consistent 'Buy' ratings from analysts, with a stable 12-month price target of $37.00. The company has shown a 34.97% revenue growth over the past three months, though its growth rate is below the healthcare sector average. Pharming's financial health is strong, with efficient cost management and a prudent debt strategy.
The consistent 'Buy' ratings and stable price target suggest positive sentiment from analysts, which is likely to support the stock price. The company's strong financial health and revenue growth, despite being below sector average, further bolster investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100